“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in GBP
Last close As at 26/05/2023
GBP0.14
▲ 0.25 (1.88%)
Market capitalisation
GBP79m
e-therapeutics is a UK biotech using its proprietary computational biology and RNAi platforms to discover novel disease targets and therapies. The company is specifically focused on leveraging its expertise to design treatments targeting one cell type in the liver, hepatocytes.
Managing Director - Head of Content, Healthcare
Ali Mortazavi
CEO
Laura Roca-Alonso
Chief business officer
Forecast net debt (£m)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 0.4 | (20.6) | (29.8) |
| Relative | 4.2 | (17.3) | (29.5) |
| 52 week high/low | 23.0p/10.5p |
e-therapeutics is a biotech leveraging its validated computational biology platform to identify novel, liver-associated targets and expand its internal pipeline of short interfering RNA (siRNA or RNAi) therapeutics. In addition to the advantages of focusing on a single cell type (hepatocytes), the company’s recent strategic commitment to large language model (LLM) technologies has the potential to provide accelerated access to effective new drugs. RNAi medicines are a rapidly evolving drug class, with five drugs currently that use this technology. We view RNAi as a key growth market for e therapeutics. At end-January 2023, the company had a net cash position of £31.7m, supported by a capital raise of £13.4m (net proceeds) in September 2022.
| Y/E Jan | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (fd) (p) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 0.3 | (4.4) | (4.5) | (0.99) | N/A | N/A |
| 2022A | 0.5 | (9.4) | (9.5) | (1.65) | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024E | N/A | N/A | N/A | N/A | N/A | N/A |
Get access to the very latest content matched to your personal investment style.
